NCT03765541 2025-04-10
DEXAML-03
University Hospital, Toulouse
Phase 3 Terminated
Clinical Trials
15 trialsNCT02013167 2024-03-05
Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Amgen
Phase 3 Terminated
NCT05329545 2023-10-26
UP-NEXT
Mersana Therapeutics
Phase 3 Terminated
NCT02288897 2022-01-19
PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
Provectus Pharmaceuticals
Phase 3 Terminated
NCT00256776 2021-10-18
MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation
European Society for Blood and Marrow Transplantation
Phase 3 Terminated
NCT02298166 2021-10-06
Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations
University of Ulm
Phase 3 Terminated
NCT01987596 2020-10-29
Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer
Barbara Ann Karmanos Cancer Institute
Phase 3 Terminated
NCT02867280 2020-02-11
Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection
Sun Yat-sen University
Phase 3 Terminated
NCT02322281 2019-08-14
TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
Clovis Oncology, Inc.
Phase 3 Terminated
NCT01892345 2019-06-26
A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)
Alexion Pharmaceuticals, Inc.
Phase 3 Terminated
NCT01470131 2018-12-19
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
AB Science
Phase 3 Terminated
NCT01309126 2017-07-13
PRIMUS
HiberCell, Inc.
Phase 3 Terminated
NCT00384150 2015-11-26
Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)
Biogen
Phase 3 Terminated
NCT00363636 2015-10-02
A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)
Biogen
Phase 3 Terminated
NCT00925548 2014-07-24
STRIDE
EMD Serono
Phase 3 Terminated